WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access RD capability and technology platform company serving the global pharmaceutical, biotechnology, and medical device industries, announced today that an Investigational New Drug (IND) application for WuXi…
Source: CFDA accepts WuXi MedImmune’s novel anti-IL6 monoclonal antibody IND application for review
Sunday, March 29, 2015
CFDA accepts WuXi MedImmune’s novel anti-IL6 monoclonal antibody IND application for review
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment